GoAI
Get started
NervGen Pharma Corp. Common stock logo

NervGen Pharma Corp. Common stock

NGEN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.86

+$0.10 · +5.68%

Aug 21, 4:00 PM ET

NGEN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

26

Expensive

Momentum

19

Strong Down

Sentiment

40

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA
CEO
Adam H. Rogers
Listed since
Feb 8, 2021
Employees
8

Market position

Day range

Current $1.86

52-week range

Current $1.86

Open
$1.83
Previous close
$1.76
Volume
531.03K
0.71× average
Average volume
747.94K
Average daily volume
Market cap
152.88M USD
Beta
0.71
Market reference 1
50-day average
$1.8226
+2.05% above average
200-day average
$3.386
-45.07% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
533.72M CAD
P/E (TTM)
-8.41×
P/B (TTM)
108.37×
P/S (TTM)
0×
EV / EBITDA
-94.43×
Earnings yield
-7.94%
Free cash flow yield
-3.51%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-1268.86%
Return on assets
-190.08%
Return on invested capital
-719.57%

Financial health

Debt / equity
0×
Current ratio
1.16×
Altman Z-score
-1.23
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−25.08M CAD-0.66%

Net income

−44.12M CAD-83.90%
Income trends across reported periods−9.69M CAD−22.21M CAD−34.73M CAD−47.25M CADOperating income, FY2021: −12.91M CADOperating income, FY2022: −22.82M CADOperating income, FY2023: −17.78M CADOperating income, FY2024: −24.92M CADOperating income, FY2025: −25.08M CADNet income, FY2021: −12.82M CADNet income, FY2022: −20.54M CADNet income, FY2023: −22.38M CADNet income, FY2024: −23.99M CADNet income, FY2025: −44.12M CADFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −12.91M CAD. Operating income FY2022 −22.82M CAD. Operating income FY2023 −17.78M CAD. Operating income FY2024 −24.92M CAD. Operating income FY2025 −25.08M CAD. Net income FY2021 −12.82M CAD. Net income FY2022 −20.54M CAD. Net income FY2023 −22.38M CAD. Net income FY2024 −23.99M CAD. Net income FY2025 −44.12M CAD.
Metric (CAD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—83.74K CAD145.01K CAD114.1K CAD42.95K CAD
Gross profit—−83.74K CAD−145.01K CAD−114.1K CAD−42.95K CAD
Research and development13.91M CAD15.66M CAD8M CAD16.43M CAD6.88M CAD
Selling, general, and administrative11.17M CAD9.17M CAD9.63M CAD6.28M CAD5.98M CAD
Operating expenses25.08M CAD24.83M CAD17.63M CAD22.71M CAD12.87M CAD
Interest income333.42K CAD812.07K CAD550.12K CAD199.62K CAD29.64K CAD
Interest expense———510.07K CAD—
Depreciation and amortization55.8K CAD83.74K CAD145.01K CAD114.1K CAD42.95K CAD
Operating income−25.08M CAD−24.92M CAD−17.78M CAD−22.82M CAD−12.91M CAD
Net income−44.12M CAD−23.99M CAD−22.38M CAD−20.54M CAD−12.82M CAD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
44%
4 beats, 5 misses, 0 met estimates
Average EPS surprise
-99.11%
9 comparable reports
Latest EPS result
-0.37
Estimate -0.06 · Miss by 510.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.01-0.14-0.28-0.41Q2 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ2 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 3, 2025: actual -0.1, estimate -0.059, surprise -68.43%, Miss. Q2 2025, reported May 15, 2025: actual -0.043, estimate -0.061, surprise +29.95%, Beat. Q3 2025, reported Aug 27, 2025: actual -0.094, estimate -0.055, surprise -71.70%, Miss. Q4 2025, reported Nov 25, 2025: actual -0.043, estimate -0.061, surprise +30.00%, Beat. Q2 2026, reported Apr 2, 2026: actual -0.258, estimate -0.064, surprise -304.58%, Miss. Q2 2026, reported May 18, 2026: actual -0.015, estimate -0.074, surprise +80.35%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.37, estimate -0.061, surprise -510.76%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.86K4.62K4.38K4.14KQ2 '26EstimateQ2 '26EstimateQ3 '26Estimate
Q2 2026, reported Apr 2, 2026: actual —, estimate 4.5K USD, surprise —, Comparison unavailable. Q2 2026, reported May 18, 2026: actual —, estimate 4.5K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual —, estimate 4.5K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.00

545.16% upside
Past 12 months12-month forecastHigh $12.00Average $12.00Low $12.00

Recent analyst actions

1 institution
HC Wainwright & Co.maintainBuy

NGEN news

globenewswire.com

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…

Read source
seekingalpha.com

NervGen Pharma: I Think The Biggest Risks Are Now Behind It

NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting…

Read source
globenewswire.com

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative…

Read source

NGEN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NGEN

research.disclaimer